Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.36 |
| ▸ | TYR | P14679 | 3/20 | 0.34 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081748 | 0.86 | EP300 (0.40) | EP300CYP19A1 | |
| SCHEMBL18080404 | 0.85 | KCNMA1 (0.52) | TYRKCNMA1HSP90AB1CYP19A1 | |
| SCHEMBL18080398 | 0.85 | DPP4 (0.33) | EP300 | |
| SCHEMBL18080402 | 0.84 | NTRK1 (0.36) | — | |
| SCHEMBL18080378 | 0.82 | EP300 (0.34) | EP300 | |
| SCHEMBL16631732 | 0.82 | EP300 (0.41) | EP300CYP19A1 | |
| SCHEMBL22327308 | 0.81 | CDK1 (0.33) | — | |
| SCHEMBL18080369 | 0.79 | MPO (0.48) | TYRKCNMA1CYP19A1 | |
| SCHEMBL18080401 | 0.79 | NPC1 (0.49) | CYP19A1 | |
| SCHEMBL18080397 | 0.78 | PTGDR2 (0.36) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | EP300 4033/4885TYR 3563/4885KCNMA1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.